welcome to neurology live®Friday 5! The staff puts together five highlights each week. neurology live®From newsworthy research findings and FDA actions, to expert interviews and peer-to-peer panel discussions on neurology.
1: 5 neurology clinical trial results to watch in 2023
Over the years, drug development has continued to boom across neurology, with record amounts of funding and the introduction of the first-ever disease-modifying therapies. There are hundreds of ongoing trials evaluating potential agents for patients with neurological conditions across various stages. Discover five clinical trials with data readouts expected in 2023. neurology live® attracts attention.
2: peer exchange: Management of Amyloid-Associated Imaging Abnormalities (ARIA) in Alzheimer’s Disease
in episode 14 of this peer exchangea panel of dementia experts commented on their observation of amyloid-associated imaging abnormalities (ARIA) seen in many Alzheimer’s disease treatments and shared their thoughts on the management of ARIA. neurology live® Series Panel Features Marwan Sabbagh, MD; Alireza Atri, MD, PhD. Sharon Cohen, MD, FRCPC; and Eric McDade, DO.
3: NeuroVoices: Rachel Alvarez on identifying critical therapeutic needs in congenital muscular dystrophy
In the latest edition of our in-depth Q&A series, the Executive Director of Cure CMD discusses the treatment status and improvements in CMD. She spoke about the need for increased awareness, early detection, and the role neurologists play earlier in a patient’s life.In addition, she spoke about the current state of gene therapy, remaining challenges, and how these We talked about why the approach doesn’t work as well for adults with her CMD.
4: A Case Study and Overview of WAKIX® (Pitrizant) Tablets in the Treatment of Excessive Daytime Sleepiness and/or Cataplexies in Adults with Narcolepsy
Director of the Center for Sleep and Arousal Disorders at Montefiore Medical Center and Professor of Neurology at the Albert Einstein College of Medicine presented data on the safety and efficacy of WAKIX® (an analgesic) from clinical studies, as well as patient clinical case studies. I reviewed. Narcolepsy type 1 treated with WAKIX. This is the first and only FDA-approved unscheduled treatment option for this patient group.
5: Education and relaxation of multidisciplinary care teams to treat Parkinson’s disease: Eli Pollard
The Parkinson Foundation’s Chief Training and Education Officer provided perspective on the various community providers who could benefit from this series. Additionally, she spoke about the most troublesome symptoms patients face and why they need a balanced group of clinicians to tackle such problems. [WATCH TIME: 4 minutes]